联合药物方案对肝移植术中缺血再灌注损伤严重程度的影响:一项随机临床试验
这项在比利时进行的单中心、研究者驱动、开放标签、2平行臂随机临床试验,于2013年9月至2018年2月纳入成人首次单发全尺寸肝移植等待者,随机分为联合药物方案+标准治疗(静态冷保存)组或仅标准治疗对照组。联合药物方案包括:供肝静态冷保存后经门静脉离体灌注依前列醇;受者麻醉前口服α-生育酚和褪黑素,无肝期和再灌注期静脉给予抗凝血酶III、英夫利西单抗、脱铁转铁蛋白、重组促红细胞生成素-β、C1抑制剂和谷胱甘肽。主要终点为移植后72小时内血清AST峰值,联合药物组与对照组无显著差异(几何均值1262.9 U/L vs 1451.2 U/L;几何均值比0.87,95%CI 0.58-1.31;P=0.49)。次要终点(再灌注后综合征、缺血再灌注损伤评分、早期移植物功能障碍、手术并发症、缺血性胆管病、急性肾损伤、急性细胞性排斥反应、移植物和患者生存)两组间亦无显著差异。作者认为,针对冷保存后移植物和受者的下游联合药物策略可能还需包含针对保存期间供肝的上游策略。
要点
- 联合药物方案组与对照组移植后72小时内血清AST峰值无显著差异:几何均值1262.9 U/L(95%CI 946.3-1685.4 U/L)vs 1451.2 U/L(95%CI 1087.4-1936.7 U/L),几何均值比0.87(95%CI 0.58-1.31),P=0.49。
- 再灌注后综合征、缺血再灌注损伤评分、早期移植物功能障碍、手术并发症、缺血性胆管病、急性肾损伤、急性细胞性排斥反应、移植物和患者生存等次要终点两组间均无显著差异。
- 联合药物方案包括:供肝静态冷保存后经门静脉离体灌注依前列醇;受者麻醉前口服α-生育酚和褪黑素,无肝期和再灌注期静脉给予抗凝血酶III、英夫利西单抗、脱铁转铁蛋白、重组促红细胞生成素-β、C1抑制剂和谷胱甘肽。
- 作者认为,针对冷保存后移植物和受者的下游联合药物策略可能还需包含针对保存期间供肝的上游策略,动态保存策略可能提供合适的递送平台。
适用人群与场景
- 成人首次单发全尺寸肝移植等待者,在获得肝源时入组并随机化。
- 排除标准:急性肝衰竭、肾衰竭、治疗禁忌、参与另一项试验、拒绝、技术问题、等待移植期间死亡。
处置流程与药物剂量
- 联合药物方案组:供肝静态冷保存后,经门静脉离体灌注依前列醇;受者麻醉前口服α-生育酚和褪黑素,无肝期和再灌注期静脉给予抗凝血酶III、英夫利西单抗、脱铁转铁蛋白、重组促红细胞生成素-β、C1抑制剂和谷胱甘肽;同时给予标准治疗(静态冷保存)。
- 对照组:仅给予标准治疗(静态冷保存)。
研究设计与关键结果
- 单中心、研究者驱动、开放标签、2平行臂随机临床试验,在比利时进行,2013年9月至2018年2月,随访1年。
- 93例随机化患者中排除21例,符合方案分析纳入72例(每组36例);受者中位年龄60岁(IQR 51.7-66.2岁),男性52例(72.2%)。
- 主要终点移植后72小时内血清AST峰值:联合药物组几何均值1262.9 U/L(95%CI 946.3-1685.4 U/L)vs 对照组1451.2 U/L(95%CI 1087.4-1936.7 U/L),几何均值比0.87(95%CI 0.58-1.31),P=0.49。
- 次要终点(再灌注后综合征、缺血再灌注损伤评分、早期移植物功能障碍、手术并发症、缺血性胆管病、急性肾损伤、急性细胞性排斥反应、移植物和患者生存)两组间均无显著差异。
- AST单位换算:乘以0.0167转换为μkat/L。
证据类型、等级与局限
- 证据类型:随机临床试验(单中心、研究者驱动、开放标签、2平行臂)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该联合药物方案(依前列醇离体灌注供肝;受者口服α-生育酚和褪黑素,静脉给予抗凝血酶III、英夫利西单抗、脱铁转铁蛋白、重组促红细胞生成素-β、C1抑制剂和谷胱甘肽)未能降低肝移植后缺血再灌注损伤,峰值AST与对照组无显著差异。
- 作者认为,针对冷保存后移植物和受者的下游联合药物策略可能还需包含针对保存期间供肝的上游策略,动态保存策略可能提供合适的递送平台。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: In a porcine model of liver transplant, a combined drug approach that targeted the donor graft and graft recipient reduced ischemia-reperfusion injury, a major hurdle to the success of liver transplant.
OBJECTIVE: To assess the effect of a clinical form of a perioperative combined drug approach delivered immediately before implantation to the procured liver and to the liver recipient on the degree of ischemia-reperfusion injury.
DESIGN, SETTING, AND PARTICIPANTS: This unicentric, investigator-driven, open-label randomized clinical trial with 2 parallel arms was conducted in Belgium from September 2013 through February 2018, with 1-year follow-up. Adults wait-listed for a first solitary full-size liver transplant were screened for eligibility. Exclusion criteria were acute liver failure, kidney failure, contraindication to treatment, participation in another trial, refusal, technical issues, and death while awaiting transplant. Included patients were enrolled and randomized at the time of liver offer. Data were analyzed from May 20, 2019, to May 27, 2020.
INTERVENTIONS: Participants were randomized to a combined drug approach with standard of care (static cold storage) or standard of care only (control group). In the combined drug approach group, following static cold preservation, donor livers were infused with epoprostenol (ex situ, portal vein); recipients were given oral α-tocopherol and melatonin prior to anesthesia and intravenous antithrombin III, infliximab, apotransferrin, recombinant erythropoietin-β, C1-inhibitor, and glutathione during the anhepatic and reperfusion phase.
MAIN OUTCOMES AND MEASURES: The primary outcome was the posttransplant peak serum aspartate aminotransferase (AST) level within the first 72 hours. Secondary end points were the frequencies of postreperfusion syndrome, ischemia-reperfusion injury score, early allograft dysfunction, surgical complications, ischemic cholangiopathy, acute kidney injury, acute cellular rejection, and graft and patient survival.
RESULTS: Of 93 randomized patients, 21 were excluded, resulting in 72 patients (36 per study arm) in the per protocol analysis (median recipient age, 60 years [IQR, 51.7-66.2 years]; 52 [72.2%] men). Peak AST serum levels were not different in the combined drug approach and control groups (geometric mean, 1262.9 U/L [95% CI, 946.3-1685.4 U/L] vs 1451.2 U/L [95% CI, 1087.4-1936.7 U/L]; geometric mean ratio, 0.87 [95% CI, 0.58-1.31]; P = .49) (to convert AST to μkat/L, multiply by 0.0167). There also were no significant differences in the secondary end points between the groups.
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, the combined drug approach targeting the post-cold storage graft and the recipient did not decrease ischemic-reperfusion injury. The findings suggest that in addition to a downstream strategy that targets the preimplantation liver graft and the graft recipient, a clinically effective combined drug approach may need to include an upstream strategy that targets the donor graft during preservation. Dynamic preservation strategies may provide an appropriate delivery platform.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02251041.
参考来源
- Meurisse N, Mertens M, Fieuws S, et al. Effect of a Combined Drug Approach on the Severity of Ischemia-Reperfusion Injury During Liver Transplant: A Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 36853611. doi:10.1001/jamanetworkopen.2023.0819
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。